Transfer Pricing for Swiss Companies in India
Swiss companies operating in India through subsidiaries, branch offices, or liaison offices must comply with India's transfer pricing regulations under Sections 92 to 92F of the Income Tax Act, 1961. Every international transaction between associated enterprises must be priced at arm's length, with comprehensive documentation maintained under Section 92D.
Switzerland is a major source of FDI into India. Companies like Nestle India, Novartis, Roche, ABB, Holcim (through Ambuja Cements and ACC), Zurich Insurance, and Schindler have substantial Indian operations. Nestle alone invested Rs 60-65 billion ($723-783 million) from 2020 to 2025 in expanding manufacturing capacity in India. Italy and Switzerland together form a significant European investment corridor into India.
Swiss multinationals typically operate complex group structures involving intellectual property (IP) holding companies, regional headquarters, and shared service centers. These structures generate multiple categories of intercompany transactions, from royalties and licensing fees to management services and intercompany financing, all of which require robust transfer pricing documentation.
The threshold for mandatory transfer pricing compliance in India is any international transaction exceeding Rs 1 crore in aggregate. Given the scale of Swiss operations in India, virtually every Swiss subsidiary triggers this threshold through royalty payments, component imports, management fees, or technical service charges.
How Switzerland's DTAA Affects Transfer Pricing
The India-Switzerland DTAA, originally signed in 1994 and revised in 2010, provides favorable withholding tax rates. However, a major development occurred on January 1, 2025, when Switzerland suspended the Most Favoured Nation (MFN) clause in the treaty protocol.
| Income Type | Domestic Rate (Without DTAA) | India-Switzerland DTAA Rate | Pre-2025 MFN Rate |
|---|---|---|---|
| Dividends | 20% | 10% | 5% (no longer available) |
| Interest | 20% | 10% | 10% |
| Royalties | 20% | 10% | 10% |
| Fees for Technical Services | 20% | 10% | 10% |
MFN Clause Suspension: What Changed
Prior to January 1, 2025, Switzerland applied the MFN clause to reduce dividend withholding from 10% to 5% based on India's lower rates with OECD member countries (Lithuania and Colombia). Following the Indian Supreme Court's 2023 ruling in the Nestle SA case, which held that MFN benefits require explicit notification by the Indian government under the Income Tax Act, Switzerland decided to suspend the MFN clause entirely.
This means that from January 1, 2025 onward, dividend payments between Swiss and Indian entities are subject to the base treaty rate of 10%, up from the earlier effective rate of 5%. Income accruing during 2018-2024 continues to benefit from the 5% MFN rate. This directly impacts transfer pricing structures that relied on lower dividend repatriation costs.
The MFN suspension makes transfer pricing optimization even more critical for Swiss companies. With higher dividend withholding costs, Swiss multinationals may need to reconsider their profit extraction strategy from India, potentially shifting from dividend repatriation to other mechanisms like royalties (also at 10%), management fees, or intercompany pricing adjustments, all of which must satisfy arm's length requirements.
Transfer pricing adjustments can override DTAA rates. If the Indian tax authority determines that an intercompany payment exceeds the arm's length price, the deductible expense is reduced regardless of the treaty rate. Swiss companies must ensure that all intercompany payments are robustly benchmarked to withstand scrutiny.
Document Requirements from Switzerland
Switzerland has been a member of the Hague Apostille Convention since January 11, 1965. The cantonal chancelleries or the Federal Chancellery handle apostille authentication of Swiss documents.
Transfer pricing documentation for Swiss subsidiaries in India must include:
- Form 3CEB: The accountant's report under Section 92E, certified by a chartered accountant, reporting all international transactions. Filed electronically on the Income Tax portal.
- Transfer Pricing Study (Section 92D): Comprehensive documentation covering functional analysis, comparability analysis, method selection, and arm's length price computation. Must specifically address IP-related transactions, which are common for Swiss companies.
- Tax Residency Certificate (TRC): Issued by the relevant Swiss cantonal tax authority. Must confirm the entity is a tax resident of Switzerland, not merely domiciled there. Essential for claiming DTAA benefits.
- Form 10F: Electronic self-declaration filed on the Indian Income Tax portal since July 2022.
- Master File and CbCR: Required if the Swiss parent's consolidated group revenue exceeds Rs 500 crore. Major Swiss multinationals (Nestle, Novartis, ABB, Roche) invariably exceed this threshold. Filed as Form 3CEAA and Form 3CEAD.
- IP-related documentation: For royalties and licensing arrangements, detailed evidence of the IP's ownership, development, maintenance, protection, and exploitation (DEMPE functions) is critical. Swiss group structures often centralize IP in Swiss entities, and Indian authorities scrutinize whether the Indian subsidiary should receive a larger share of the IP-related profits.
- Apostilled corporate documents: Certificate of incorporation, articles of association, board resolutions, and intercompany agreements from the Swiss parent.
Step-by-Step Transfer Pricing Process
Step 1: Identify All International Transactions
Map every transaction between the Indian subsidiary and the Swiss parent or group entities. Common categories for Swiss companies include royalties for technology, brand, and patent licensing (very common for pharma, food, and engineering companies), management and corporate support services, IT and shared service charges, purchase of raw materials, ingredients, and components, intercompany loans and treasury management, corporate guarantees, and cost contribution arrangements for R&D.
Step 2: DEMPE Analysis for IP Transactions
Swiss companies frequently centralize IP ownership in Switzerland. Indian tax authorities, following OECD BEPS guidelines, examine the Development, Enhancement, Maintenance, Protection, and Exploitation (DEMPE) functions to determine whether the Swiss entity is the genuine IP owner or merely a legal owner. If the Indian subsidiary performs significant DEMPE functions (e.g., local R&D adaptation, marketing intangibles, quality control), a larger share of IP-related returns may be attributed to India.
Step 3: Conduct Functional and Risk Analysis
Perform detailed FAR analysis for both entities. Swiss subsidiaries in India may operate as full-fledged manufacturers (performing complete manufacturing with own brand), contract manufacturers (manufacturing to Swiss parent specifications), limited-risk distributors (distributing products with minimal marketing risk), or commissionnaires (acting as sales agents for the Swiss parent). The characterization determines the appropriate profit allocation.
Step 4: Select Appropriate Transfer Pricing Method
For Swiss-India transactions:
- Royalties: CUP method using comparable license agreements, or TNMM with the Indian entity as the tested party. Pharma royalties are heavily scrutinized, with Indian authorities often questioning rates exceeding 3-5% of net sales.
- Manufacturing: TNMM using operating profit/total cost or CPM for contract manufacturing arrangements.
- Management services: CPM or TNMM, with emphasis on demonstrating tangible benefit to the Indian subsidiary.
- Intercompany loans: CUP using reference rates adjusted for credit risk.
- Brand royalties: CUP or TNMM, with specific attention to whether the Indian entity contributes to local brand development.
Step 5: Benchmark and Compute Arm's Length Price
Use Indian databases to identify comparable companies. Apply interquartile range with tolerance bands of 1% (wholesale trading) or 3% (all other transactions) per CBDT notification No. 157/2025. For royalties, use global databases like RoyaltyStat or ktMINE to identify comparable licensing arrangements.
Step 6: Prepare Documentation and File
File Form 3CEB by October 31. File ITR-6 by November 30. File Master File (Form 3CEAA) by November 30. File CbCR (Form 3CEAD) within 12 months of the Swiss parent's financial year end. Ensure the TRC is obtained from the cantonal tax authority and Form 10F is filed before the ITR.
Timeline and Costs
| Compliance Activity | Deadline | Estimated Cost (INR) |
|---|---|---|
| Transfer Pricing Study | Before Form 3CEB filing | 3,00,000-20,00,000 |
| Form 3CEB Filing | October 31 | Included in TP study |
| Master File (Form 3CEAA) | November 30 | 2,00,000-5,00,000 |
| CbCR (Form 3CEAD) | 12 months from FY end | 1,50,000-3,00,000 |
| Income Tax Return (ITR-6) | November 30 | 50,000-2,00,000 |
| APA Application | Voluntary, anytime | 15,00,000-60,00,000 |
| Statutory Audit (Form 3CA/3CD) | Before ITR due date | 1,50,000-8,00,000 |
Total annual transfer pricing compliance costs for a Swiss subsidiary in India typically range from Rs 8-30 lakh, reflecting the higher complexity of IP-heavy Swiss group structures. Large Swiss multinationals with multiple transaction categories may spend significantly more. The timeline from study commencement to final filing is 6-10 weeks.
Common Challenges for Swiss Companies
MFN Suspension Impact on Repatriation Strategy
The suspension of the MFN clause from January 1, 2025, doubled the effective dividend withholding rate from 5% to 10%. Swiss multinationals with Indian subsidiaries must reassess their profit repatriation strategies. Options include increasing royalty payments (still at 10% but deductible from Indian taxable income, unlike dividends), restructuring management fee arrangements, or retaining profits in India for reinvestment. Each alternative must satisfy transfer pricing arm's length requirements.
Pharma and Food Sector Royalty Disputes
Indian tax authorities are particularly aggressive in scrutinizing royalties paid by Indian pharma and food subsidiaries to Swiss parents. Companies like Nestle India and Novartis have faced transfer pricing assessments on brand royalties and technology licensing fees. The tax authorities often argue that the Indian subsidiary has developed significant local marketing intangibles and should not pay royalties at the rates charged by the Swiss parent. Maintaining detailed DEMPE documentation is essential.
Cost Contribution Arrangement Scrutiny
Swiss companies often use Cost Contribution Arrangements (CCAs) for group-wide R&D. Indian tax authorities examine whether the Indian subsidiary's contribution is commensurate with the expected benefits. If the CCA payments are disproportionate to the Indian entity's use of the R&D output, the transfer pricing officer may disallow the excess as a non-arm's length payment.
Intercompany Financing Complexity
Swiss companies frequently use centralized treasury structures. Intercompany loans from Swiss treasury entities to Indian subsidiaries must be priced at arm's length, with Indian authorities typically benchmarking against Indian borrowing rates rather than Swiss or LIBOR/SOFR-based rates. RBI's ECB regulations impose additional ceiling rates and end-use restrictions on foreign currency borrowings. The interaction between transfer pricing, ECB rules, and FEMA regulations creates compliance complexity.
Secondary Adjustment and Repatriation
Transfer pricing adjustments exceeding Rs 1 crore trigger secondary adjustment requirements under Section 92CE. The excess must be repatriated within 90 days or imputed interest is charged. For Swiss companies with complex group structures, coordinating the secondary adjustment repatriation with Swiss withholding tax obligations and group treasury policies adds a layer of compliance.
Why Choose BeaconFiling
We provide specialized transfer pricing services for Swiss companies operating in India. Our team understands IP-heavy group structures, pharmaceutical and food sector royalty benchmarking, and the impact of the MFN clause suspension.
- Transfer pricing documentation — TP studies, DEMPE analysis, Form 3CEB certification, and royalty benchmarking
- Tax advisory — DTAA structuring post-MFN suspension, APA applications, and profit repatriation optimization
- Corporate tax filing — ITR-6 preparation, advance tax computation, and withholding tax compliance
- Company registration — Setting up subsidiaries and branch offices for Swiss companies
We work with Swiss subsidiaries across pharmaceuticals, food processing, engineering, insurance, and financial services.
WhatsApp: +91 874 501 3644 | Email: [email protected]
Frequently Asked Questions
How does the MFN clause suspension affect Swiss companies in India?
From January 1, 2025, Switzerland suspended the MFN clause in the India-Switzerland DTAA. This increased the effective dividend withholding rate from 5% to 10%. Royalties, interest, and FTS remain at 10%. Swiss companies must reassess their profit extraction strategies and ensure alternative mechanisms satisfy transfer pricing requirements.
What withholding tax rates apply to royalty payments from India to Switzerland?
Royalties paid by an Indian subsidiary to a Swiss parent are subject to 10% withholding under the India-Switzerland DTAA. This rate has not changed with the MFN suspension. However, the transfer pricing officer may challenge the quantum of the royalty if it exceeds arm's length benchmarks, reducing the deductible expense in India.
Is DEMPE analysis mandatory for Swiss companies with IP in India?
While not explicitly mandated by Indian statute, DEMPE analysis is effectively required for any transfer pricing study involving IP-related transactions. Indian tax authorities follow OECD BEPS guidelines and examine which entity performs Development, Enhancement, Maintenance, Protection, and Exploitation functions. Swiss companies centralizing IP must demonstrate that the Swiss entity genuinely owns and manages the IP.
Can Swiss companies apply for Bilateral APAs with India?
Yes. India and Switzerland have an active competent authority relationship enabling Bilateral APAs. CBDT signed 64 bilateral APAs in FY 2024-25. A BAPA covers 3-5 prospective years with rollback and provides certainty on royalty rates, management fees, and other intercompany pricing. Given the complexity of Swiss-India structures, APAs are strongly recommended.
What are the penalties for transfer pricing non-compliance?
Penalties include 2% of each international transaction value for not maintaining documentation (Section 271AA), Rs 1 lakh for failure to file Form 3CEB (Section 271BA), and up to 200% of tax on adjustments for under-reporting income (Section 270A). Secondary adjustment non-compliance results in imputed interest at SBI's marginal lending rate plus 3.25%.
Are Safe Harbour Rules available for Swiss companies in India?
Yes. CBDT extended Safe Harbour Rules for AY 2025-26 and AY 2026-27 with a transaction threshold of Rs 300 crore. Eligible transactions include IT/ITeS, KPO, contract R&D, and core auto component manufacturing. Swiss companies in eligible sectors can opt for safe harbour to eliminate transfer pricing disputes.
How should intercompany loans from Swiss treasury entities be priced?
Indian tax authorities typically benchmark intercompany loans using Indian market rates and the borrower's creditworthiness, not Swiss or LIBOR/SOFR rates. RBI's ECB regulations impose ceiling rates. The CUP method using comparable Indian borrowing data or bank quotes is the most accepted approach. Credit rating adjustments should be documented.